Berger & Montague is Co-Lead Counsel for a proposed class of
direct purchasers of the anti-AIDS medicines Norvir and Kaletra.
Norvir serves as a "booster" to prolong the efficacy of other
anti-AIDS drugs. Plaintiffs allege that defendant Abbott
Laboratories quadrupled the price for Norvir, while selling Kaletra
(a combination of the active ingredient in Norvir and another AIDS
drug) below Abbott's cost. These actions were taken in order to
simultaneously increase sales of Kaletra and to suppress sales of
competitors' AIDS treatments which depend on Norvir as a
stand-alone product.